Characteristics | Resection(n = 28) | Biopsy(n = 42) | Total(n = 70) | χ2/t | P value |
---|---|---|---|---|---|
Sex | 0.972 | 0.324 | |||
Male | 18 | 22 | 40 | ||
Female | 10 | 20 | 30 | ||
Age | 47.9 ± 15.9 | 56.9 ± 12.1 | 53.3 ± 14.3 | 2.686 | 0.995 |
KPS | 84.3 ± 16.7 | 73.1 ± 13.7 | 77.6 ± 15.8 | −3.068 | 0.002 |
IELSG score | 10.303 | 0.006 | |||
Low risk(0–1) | 16 | 9 | 25 | ||
Intermediate risk(2–3) | 10 | 22 | 32 | ||
High risk(4–5) | 2 | 11 | 13 | ||
Present symptoms | |||||
Headache | 15 | 30 | 45 | 2.333 | 0.127 |
Limb weakness | 12 | 22 | 34 | 0.610 | 0.435 |
Mental impairment | 8 | 18 | 26 | 1.469 | 0.226 |
Aphasia | 3 | 7 | 10 | 0.486 | 0.486 |
Ataxia | 3 | 5 | 8 | 0.024 | 0.878 |
Seizure | 2 | 3 | 5 | 0.000 | 1.000 |
Other | 3 | 2 | 5 | 0.897 | 0.343 |
Duration of symptoms | 4.3 ± 7.2 | 6.9 ± 13.3 | 5.8 ± 11.2 | 0.945 | 0.826 |
Numbers of tumors | 14.593 | 0.000 | |||
Single | 23 | 15 | 38 | ||
Multiple | 5 | 27 | 32 | ||
The maximum diameter of the target | 30.2 ± 10.6 | 29.7 ± 8.7 | 29.9 ± 9.5 | −0.216 | 0.415 |
Location | 22.451 | 0.000 | |||
Deep location | 1 | 16 | 17 | ||
Infratentorial | 3 | 14 | 17 | ||
Supratentorial | 24 | 12 | 36 | ||
Adjuvant therapies | 1.324 | 0.516 | |||
Chemotherapy | 14 | 18 | 32 | ||
Radiotherapy | 5 | 5 | 10 | ||
Chemotherapy and radiotherapy | 9 | 19 | 28 | ||
Changes in symptoms | 19.973 | 0.000 | |||
Aggravation | 5 | 10 | 15 | ||
Improvement | 14 | 2 | 16 | ||
Static | 9 | 30 | 39 | ||
Complication | 0.273 | 0.601 | |||
No | 25 | 39 | 64 | ||
Yes | 3 | 3 | 6 | ||
Overall survival | 23.4 ± 13.0 | 11.2 ± 6.2 | 16.1 ± 11.2 | −5.263 | 0.000 |
Progression-free survival | 8.6 ± 4.7 | 4.6 ± 3.2 | 6.2 ± 4.3 | −4.241 | 0.000 |